<DOC>
	<DOCNO>NCT00590837</DOCNO>
	<brief_summary>A multicenter randomize trial compare induction therapy ( IC : Idarubicin Cytarabine , 5 + 7 ) ICL ( drug plus lomustine ( CCNU ) , 200 mg/m2 orally day 1 ) . Patients complete remission ( CR ) receive post-remission schedule without lomustine accord randomization . Patients 60 65 year old propose reduced conditioning allogeneic transplantation first consolidation .</brief_summary>
	<brief_title>Adding Lomustine Chemotherapy Older Patients With Acute Myelogenous Leukemia ( AML ) , Allogeneic Transplantation Patients From 60 65 Years Old</brief_title>
	<detailed_description>- Principal Objective : The primary objective study assess ability lomustine increase overall survival add lomustine induction post-remission chemotherapy . - Secondary Objectives : - To assess ability lomustine increase CR rate . - To assess ability lomustine increase event-free survival . - To evaluate toxicity side-effects lomustine . - To evaluate feasibility reduce condition allogeneic transplantation *between 60 65 year old . - To evaluate prognostic factor . - To evaluate QOL elderly . - Study design : Parallel - Study plan : - Induction therapy : Patients randomize receive idarubicin ( 5d ) plus cytarabine drug plus lomustine , latter give dose 200 mg/m2 orally day 1 . - Consolidation therapy : After complete induction treatment , patient complete remission receive course consolidation therapy idarubicin ( 3d ) subcutaneous cytarabine . - Maintenance therapy : In patient persist CR one month complete consolidation : six course monthly combination chemotherapy ( idarubicin ( 1d ) subcutaneous cytarabine ) continuous regimen methotrexate 6-mercaptopurine , 6 month . - Allogeneic transplantation : Patients 60 65 year old full match donor receive consolidation ( still CR ) alloBMT reduce condition regimen Fludarabine ( 3d ) TBI ( 2Gy ) . - Number subject : 460</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<criteria>Patients age 60 year old de novo AML nonpoor cytogenetic feature . Patients unfavourable cytogenetic ( base GOELAMSBGMT criterion ) Performance status Sorror score &lt; 3 . Signed date informed consent . Acute promyelocytic leukemia . Patients myeloproliferative syndrome prior diagnosis AML . Patients previously myelodysplastic syndrome . Positive serology HIV . Patients unfavourable cytogenetic Patients isolate medullary extra localization disease</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>AML</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>old</keyword>
	<keyword>De novo AML</keyword>
</DOC>